The goal of this Specialized Program of Research Excellence (SPORE) in pancreas cancer is to translate outstanding hypothesis-driven basic research into clinical treatment that saves lives. Pancreatic cancer is a devastating cancer that kills patients not just because it may be extremely aggressive but also because it is diagnosed late. This SPORE is a unique collaboration between Georgetown University, Geisinger Health System and INDIVUMED a German Research Institute with a German hospital consortium that brings together an outstanding academic institution, a large regional healthcare system and a German basic and clinical research system to address the biology of pancreatic cancer and clinical care. Project 1 focuses on inhibition of pleiotrophin, a novel heparin-binding growth factor that promotes invasion and metastasis in pancreatic cancer. Project 2 focuses on the role of neuregulins and pleiotrophin in an established model of neuron:tumor cell interaction with the goal of developing methods to block neural invasion by malignant pancreas cells that may ultimately aid in disease palliation. Project 3 focuses on recent findings that inhibition of the nuclear receptor coactivator AIB1 within pancreas cancer cells and adjacent endothelium may block signaling from multiple growth factors to enhance apoptosis. The activation of the ras/MAP kinase pathway that occurs in up to 90% of pancreas cancer is the focus for novel approaches to radiation sensitization in Proiect 4. Investigators at Georgetown have developed a rafl antisense inhibitor that is already in Phase I trial and have developed other molecular targets in the pathway that are complementary. In addition, this SPORE is developing the infrastructure and resources to acquire tissues and bodily fluids from patients (Pancreatic Tumor Bank and Serum Detection & Molecular Identification Cores) with an expected 120 curative resections a year. The SPORE will utilize a biostatistical core to insure that all projects have appropriate designs, methods of analysis, and an integrated database for reporting patient outcomes. Further, the SPORE will support developmental projects designed to generate new knowledge and approaches to early detection and promote the development of career tracks dedicated to translational research in pancreatic cancer. This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA108440-05
Application #
7247994
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Program Officer
Ault, Grace S
Project Start
2003-09-30
Project End
2008-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
5
Fiscal Year
2007
Total Cost
$209,700
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Rapisuwon, Suthee; Vietsch, Eveline E; Wellstein, Anton (2016) Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J 14:211-22
LaConti, Joseph J; Laiakis, Evagelia C; Mays, Anne Deslattes et al. (2015) Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma. BMC Genomics 16 Suppl 1:S1
Sharif, G M; Schmidt, M O; Yi, C et al. (2015) Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene 34:5879-89
Vietsch, Eveline E; van Eijck, Casper Hj; Wellstein, Anton (2015) Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer. Pancreat Disord Ther 5:
Shivapurkar, Narayan; Weiner, Louis M; Marshall, John L et al. (2014) Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One 9:e84686
Shivapurkar, N; Mikhail, S; Navarro, R et al. (2013) Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. Int J Colorectal Dis 28:887
Wellstein, Anton (2012) ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers. Front Oncol 2:192
LaConti, Joseph J; Shivapurkar, Narayan; Preet, Anju et al. (2011) Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 6:e20687
Wellstein, Anton; Toretsky, Jeffrey A (2011) Hunting ALK to feed targeted cancer therapy. Nat Med 17:290-1
Stylianou, D C; Auf der Maur, A; Kodack, D P et al. (2009) Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28:3296-306

Showing the most recent 10 out of 11 publications